Title: Clinical value of systemic immunoinflammatory index in predicting recurrence and
metastasis in patients with primary liver cancer
Version: 2 Date: 07 Dec 2024
Reviewer's report:
This is an easy-to-understand paper regarding the Clinical value of systemic
immunoinflammatory index in predicting recurrence and metastasis in patients with primary
liver cancer. The authors have generally performed appropriate analyses.
There is some concern about this paper.
1. In “General Information”, Exclusion criteria, what is the mean of " (4) Patients with surgical
margins < 1cm or combined with other organ metastases such as the lungs and brain". This
seems to repeat with Inclusion criteria: (3) Preoperative imaging examination showed that the
tumor had no distant metastasis and lymph nodes metastasis.
2. Recurrence and metastasis are two different concepts. The definitions of “recurrence and
metastasis” used as the endpoint in this article are unclear. It is recommended that they be
redefined or named.
3. In Table 1, the “tumor capsule” is divided into “yes” and “no,” which does not seem to reflect
its detailed information. It is recommended that it be classified as “complete,”” incomplete,”
and “absence.”
4. How were recurrence and metastasis assessed, and what specific cases of recurrence and
metastasis were observed? Detailed information on recurrence and metastasis events should be
included in the results section.
5. The endpoint events observed in this study are time-dependent, making the use of a logistic
regression model less appropriate. It is recommended to use a Cox proportional hazards
regression model for analysis and to supplement the results with Kaplan-Meier survival curves.
Title: Clinical value of systemic immunoinflammatory index in predicting recurrence and
metastasis in patients with primary liver cancer
Version: 2 Date: 07 Dec 2024
Reviewer's report:
This is an easy-to-understand paper regarding the Clinical value of systemic
immunoinflammatory index in predicting recurrence and metastasis in patients with primary
liver cancer. The authors have generally performed appropriate analyses.
There is some concern about this paper.
1. In “General Information”, Exclusion criteria, what is the mean of " (4) Patients with surgical
margins < 1cm or combined with other organ metastases such as the lungs and brain". This
seems to repeat with Inclusion criteria: (3) Preoperative imaging examination showed that the
tumor had no distant metastasis and lymph nodes metastasis.
2. Recurrence and metastasis are two different concepts. The definitions of “recurrence and
metastasis” used as the endpoint in this article are unclear. It is recommended that they be
redefined or named.
3. In Table 1, the “tumor capsule” is divided into “yes” and “no,” which does not seem to reflect
its detailed information. It is recommended that it be classified as “complete,”” incomplete,”
and “absence.”
4. How were recurrence and metastasis assessed, and what specific cases of recurrence and
metastasis were observed? Detailed information on recurrence and metastasis events should be
included in the results section.
5. The endpoint events observed in this study are time-dependent, making the use of a logistic
regression model less appropriate. It is recommended to use a Cox proportional hazards
regression model for analysis and to supplement the results with Kaplan-Meier survival curves.
Please review this paper.
user
Title: Clinical value of systemic immunoinflammatory index in predicting recurrence and
metastasis in patients with primary liver cancer
Version: 2 Date: 07 Dec 2024
Reviewer's report:
This is an easy-to-understand paper regarding the Clinical value of systemic
immunoinflammatory index in predicting recurrence and metastasis in patients with primary
liver cancer. The authors have generally performed appropriate analyses.
There is some concern about this paper.
1. In “General Information”, Exclusion criteria, what is the mean of " (4) Patients with surgical
margins < 1cm or combined with other organ metastases such as the lungs and brain". This
seems to repeat with Inclusion criteria: (3) Preoperative imaging examination showed that the
tumor had no distant metastasis and lymph nodes metastasis.
2. Recurrence and metastasis are two different concepts. The definitions of “recurrence and
metastasis” used as the endpoint in this article are unclear. It is recommended that they be
redefined or named.
3. In Table 1, the “tumor capsule” is divided into “yes” and “no,” which does not seem to reflect
its detailed information. It is recommended that it be classified as “complete,”” incomplete,”
and “absence.”
4. How were recurrence and metastasis assessed, and what specific cases of recurrence and
metastasis were observed? Detailed information on recurrence and metastasis events should be
included in the results section.
5. The endpoint events observed in this study are time-dependent, making the use of a logistic
regression model less appropriate. It is recommended to use a Cox proportional hazards
regression model for analysis and to supplement the results with Kaplan-Meier survival curves.
assistant